1. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study 
Thomas B. Casale, MD, Allan T. Luskin, MD, William Busse, MD, Robert S. Zeiger, MD, PhD, Benjamin Trzaskoma, MS, Ming Yang, PhD, Noelle M. Griffin, PhD, Bradley E. Chipps, MD 
The Journal of Allergy and Clinical Immunology: In Practice 
Volume 7, Issue 1, Pages e1 (January 2019)
DOI: /j.jaip
Copyright © 2019 The Authors Terms and Conditions

2. Figure 1
Patient disposition. Noncompliance was defined as an indication that a patient has not agreed with or followed the instructions related to the protocol.
The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e1DOI: ( /j.jaip )
Copyright © 2019 The Authors Terms and Conditions

3. Figure 2
Mean exacerbation rate by (A) age group and (B) biomarker status. *P < for comparison of before study entry to through 12 months on study for each age group (calculation based on simulation). Sum of exacerbations is not adjusted to patient's time on study. †Baseline: mean ± SD; through month 12: least squares (mean). ‡P values reflect adjustments for differences in baseline characteristics.
The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e1DOI: ( /j.jaip )
Copyright © 2019 The Authors Terms and Conditions

4. Figure 3
Percentage of patients with 1 or more hospitalizations by (A) age group and (B) biomarker status.
The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e1DOI: ( /j.jaip )
Copyright © 2019 The Authors Terms and Conditions

5. Figure 4
Mean prebronchodilator FEV1 (L) by age group (for patients with spirometry at baseline and end of the study).
The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e1DOI: ( /j.jaip )
Copyright © 2019 The Authors Terms and Conditions

6. Figure 5
Mean ACT score 12 months after omalizumab initiation by (A) age group and (B) asthma severity.
The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e1DOI: ( /j.jaip )
Copyright © 2019 The Authors Terms and Conditions

7. Figure 6
Impact of biomarker status on ACT outcomes. (A) Mean change from baseline in ACT score 12 months after omalizumab initiation in adults. (B) Percentage of patients with well-controlled asthma. P values reflect adjustment for difference in baseline characteristics. *Baseline mean ± SD; through month 12 least squares mean (SE).
The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e1DOI: ( /j.jaip )
Copyright © 2019 The Authors Terms and Conditions

8. Figure E1
Exacerbation rate before study entry and through 12 months on study for patients with IgE levels outside the limits of the omalizumab dosing table.
The Journal of Allergy and Clinical Immunology: In Practice 2019 7, e1DOI: ( /j.jaip )
Copyright © 2019 The Authors Terms and Conditions